BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 29310602)

  • 1. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
    Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
    PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL; Ding A
    Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
    Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
    Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
    Sanges F; Floris M; Cossu-Rocca P; Muroni MR; Pira G; Urru SAM; Barrocu R; Gallus S; Bosetti C; D'Incalci M; Manca A; Uras MG; Medda R; Sollai E; Murgia A; Palmas D; Atzori F; Zinellu A; Cambosu F; Moi T; Ghiani M; Marras V; Santona MC; Canu L; Valle E; Sarobba MG; Onnis D; Asunis A; Cossu S; Orrù S; De Miglio MR
    BMC Cancer; 2020 Jun; 20(1):491. PubMed ID: 32487046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer.
    Yao MS; Kurland BF; Smith AH; Schubert EK; Dunnwald LK; Byrd DR; Mankoff DA
    Ann Surg Oncol; 2007 Oct; 14(10):2985-93. PubMed ID: 17564747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
    ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
    Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
    Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
    Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
    Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
    J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic significance of ECT2 in invasive breast cancer.
    Wang HK; Liang JF; Zheng HX; Xiao H
    J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.